Eusalus Life Science

Eusalus is a biotechnology company focused on the discovery and development of next-generation inhibitors of the complement system to treat rare and severe diseases. The company was founded by industry veterans with significant expertise in complement biology, specifically targeting the alternative pathway to address unmet needs in hematology and ophthalmology. Their lead research efforts center on developing potent, orally bioavailable small molecule inhibitors of Complement Factor D. Eusalus aims to provide superior therapeutic options for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy. The firm is supported by a strong syndicate of life science investors, including OrbiMed and RA Capital Management.